, Volume 41, Issue 1, pp 34-44
Date: 04 Mar 2008

Graft-versus-host disease and immunosuppression

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content


In the last four decades, allogeneic hematopoietic stem cell transplant (HSCT) has been established as a curative therapy for many otherwise fatal diseases. Since 1968, from the time of the first successful allogeneic bone marrow transplant in a child with severe combined immune deficiency disease [1], tremendous progress has been made in this field of medicine that now we have ventured from perfect molecular matched sibling donor HSCT to unrelated donor and haploidentical donor HSCT [26] with successful outcome of the procedure. The success of these procedures in the treatment of lethal diseases has given us the courage of performing allogeneic HSCT transplant in sub-lethal diseases such as thalassemia and sickle-cell anemia. However, the procedure of HSCT transplant is associated with some very serious and fatal complications such as acute organ toxicity, especially sinusoidal obstruction syndrome infections, graft-versus-host disease (GvHD), and immune deficiency.

Presented at the First Robert A Good Society Symposium, St. Petersburg, FL 2006.